MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
KRYS — Krystal Biotech, Inc. Common Stock
NasdaqKrystal Biotech, Inc. Common Stock
$334.85
+12.57(+3.90%)
- O
- 323.76
- H
- 339.69
- L
- 321.37
- V
- 336.27K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About KRYS
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateSep 20, 2017
Employees295
Stock ExchangeNasdaq
Ticker SymbolKRYS
Websitehttps://www.krystalbio.com
Key Financial Statistics
| Market Cap | $9.54B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $179.19 - $382.54 |
| 52-Week Avg Volume | 321.6K |
| VWAP | $333.08 |
| Transactions | 13,686 |
| Total Recorded Bars | 2,272 days |